First Business Financial Services Inc. Buys 101 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by on Apr 29th, 2023

First Business Financial Services Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,036 shares of the company’s stock after acquiring an additional 101 shares during the quarter. First Business Financial Services Inc.’s holdings in Johnson & Johnson were worth $1,950,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Veracity Capital LLC increased its stake in Johnson & Johnson by 1.2% during the 4th quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock worth $888,000 after buying an additional 59 shares in the last quarter. Sandy Cove Advisors LLC increased its position in shares of Johnson & Johnson by 1.6% during the third quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock worth $605,000 after purchasing an additional 60 shares in the last quarter. LCM Capital Management Inc raised its stake in Johnson & Johnson by 0.7% in the 4th quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock valued at $1,667,000 after purchasing an additional 61 shares during the last quarter. Arbor Investment Advisors LLC lifted its holdings in Johnson & Johnson by 2.3% in the 4th quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock valued at $476,000 after purchasing an additional 61 shares in the last quarter. Finally, Mason & Associates Inc grew its holdings in shares of Johnson & Johnson by 4.9% during the third quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock worth $215,000 after buying an additional 62 shares in the last quarter. 67.94% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $163.70 on Friday. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $183.35. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The company has a 50 day moving average price of $157.80 and a 200 day moving average price of $166.99. The stock has a market capitalization of $426.32 billion, a P/E ratio of 34.25, a PEG ratio of 2.77 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping the consensus estimate of $2.51 by $0.17. The business had revenue of $24.75 billion during the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a return on equity of 35.53% and a net margin of 13.22%. The company’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period last year, the business posted $2.67 earnings per share. Equities research analysts forecast that Johnson & Johnson will post 10.67 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 2.91%. The ex-dividend date is Monday, May 22nd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio is currently 94.56%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on JNJ shares. Raymond James decreased their price target on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 19th. SVB Leerink lowered their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday, January 20th. Piper Sandler cut their price target on Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 1st. Finally, StockNews.com initiated coverage on Johnson & Johnson in a report on Thursday, March 16th. They set a “strong-buy” rating on the stock. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $173.00.

Insider Activity

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.20% of the company’s stock.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.